New Zealand markets closed

Acticor Biotech SAS (ALACT.PA)

Paris - Paris Delayed price. Currency in EUR
Add to watchlist
0.5680-0.0020 (-0.35%)
At close: 03:30PM CEST

Acticor Biotech SAS

Hôpital Bichat
INSERM U1148 46 rue Henri Huchard
Paris 75018
France
33 6 76 23 38 13
https://www.acticor-biotech.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees31

Key executives

NameTitlePayExercisedYear born
Dr. Gilles Avenard M.D.Founder, CEO & Director330.01kN/A1951
Ms. Sophie Lebel-Binay Ph.D.Deputy CEO, Chief Scientific Officer & GM211.2kN/A1968
Dr. Yannick Pletan M.D., M.Sc.Deputy CEO, GM & Chief Medical Officer256kN/A1953
Mr. Philippe Billiald Ph.D., Pharm.D.Scientific FounderN/AN/AN/A
Ms. Martine Jandrot-Perrus M.D., Ph.D.Scientific FounderN/AN/AN/A
Mr. Eric CohenChief Financial OfficerN/AN/AN/A
Mr. Aymeric HumblotHead of Finance & AdministrationN/AN/AN/A
Ms. Laurie JullienHead of Regulatory AffairsN/AN/AN/A
Ms. Kristell Lebozec Ph.D.Head of Pharmaceutical DevelopmentN/AN/AN/A
Ms. Victoria Rutman Pharm.D.Head of Quality AssuranceN/AN/AN/A
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Acticor Biotech SAS operates as a clinical stage biopharmaceutical company that develops drugs for the treatment for acute thrombotic diseases. The company develops glenzocimab, a humanized monoclonal antibody fragment that targets platelet glycoprotein VI. It's product glenzocimab is in Phase 2/3 clinical trial, as well as completed Phase 1b/2a for the treatment of acute ischemic stroke; and Phase 2/3 clinical trial for treatment of cerebrovascular accidents in emergency situations, as well as completed Phase 2 clinical trial for treating acute respiratory distress syndrome (covid-19). The company has collaboration agreement with the University of Birmingham for Phase 2b clinical trials of glenzocimab in treating heart attacks. The company was incorporated in 2013 and is headquartered in Paris, France.

Corporate governance

Acticor Biotech SAS’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.